期刊文献+

下肢动脉硬化闭塞症介入治疗的临床疗效及其影响因素研究 被引量:15

Arteriosclerosis Occlusion of Lower Limbs:Clinical Efficacy of Interventional Therapy and Its Risk Factors
原文传递
导出
摘要 目的:探索介入治疗下肢动脉硬化闭塞症(ASO)的临床疗效及其影响因素。方法:选择2012年10月至2013年8月我院收治的ASO患者96例,按照治疗方法将所有患者平均分成对照组和实验组,每组48例。对照组进行常规药物治疗,实验组在常规药物治疗基础上行介入手术。考察患者临床疗效及踝肱指数(ABI),并应用二元Logistic回归研究影响ASO复发的因素。结果:术后1个月、3个月、6个月、1年,随着时间的延长,ABI值呈下降趋势,且实验组患者的ABI值在各时间点均明显高于对照组,差异具有统计学意义(P<0.05)。其中对照组患者有效率为31.25%,实验组患者有效率为87.50%,实验组有效率显著高于对照组,差异具有统计学意义(P<0.05)。糖尿病和高胆固醇症可以单独影响ASO复发。结论:介入治疗ASO患者具有良好的疗效,显著提高患者的ABI,但术后需严格控制血糖和血脂。 Objective: To explore the clinical efficacy of interventional therapy for atherioselerosis obliterans (ASO) of Lower Limbs and its risk factors. Method: A total of 96 patients with ASO of of Lower Limbs, who were treated in West Shanghai Tongren Hospital from October 2012 to August 2013, according to the treatment method, were averagely divided into control group (n=48) and experimental group (n=48). The control group was treated with routine medicine, while the experimental group underwent interventional therapy on the basis of routine medicine. The clinical efficacy and the ankle brachial index(ABI) in the two groups were observed and the binary Logistic regression was used to study the risk factors of postoperative recurrence. Results: The ABI values gradually decreased 1 month, 3 months, 6 months, 1 year after treatment, and the ABI values of experimental group at each time point were significantly higher than those of control group, the differences were statistically significant (P〈0.05). The effective rate (31.25%) of control group was significantly lower than that (87.50%) of experimental group, the difference was statistically significant (P〈0.05). Diabetes and high cholesterol were the risk factors of postoperative recurrence. Conclusions: Interventional therapy has a good clinical efficacy in the treatment of patients with ASO of Lower Limbs, which can significantly improve the ABI values of patients, but the blood glucose and blood lipid should be strictly controlled after treatment.
出处 《现代生物医学进展》 CAS 2015年第32期6275-6278,共4页 Progress in Modern Biomedicine
关键词 下肢动脉硬化闭塞症 介入治疗 临床疗效 踝肱指数 影响因素 Arteriosclerosis occlusion of lower limbs Interventional therapy Clinical efficacy Ankle brachial index Risk factors
  • 相关文献

参考文献1

二级参考文献36

  • 1Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
  • 2Maher VM. Coronary atherosclerosis stabilization: an achievable goal.Atherosclerosis 1995; 118 (Suppl): S91-S101.
  • 3Yamashita S, Matsuzawa Y. Where are we with Probucol: A new life for an old drug? Atherosclerosis 2009; 207: 16-23.
  • 4Chiesa G, Michelagnoli S, Cassinotti M, et al. Mechanisms of high-density lipoprotein reduction after Probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism 1993; 42: 229-235.
  • 5Ishigami M, Yamashita S, Sakai N, et al. High-density lipoproteins from Probucol-treated patients have increased capacity to promote cholesterol effiux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur d Clin Invest 1997; 27: 285-292.
  • 6Hirano K, Ikegami C, Tsujii K, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Bio12005; 25: 2422-2427.
  • 7Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phospholipids and elevated prebetal-HDL without delayed conversion into alpha-migrating HDL: Putative role of angiopoietin-like protein 3 in Probucol-induced HDL remodeling. Atherosclerosis 2008; 200: 329-335.
  • 8Stocker R. Molecular mechanisms underlying the antiathero- sclerotic and antidiabetic effects of Probucol, succinobucol, and other Probucol analogues. Curr Opin Lipidol 2009; 20: 227-235.
  • 9Matsuzawa Y, Yamashita S, Funahashi T, et aL Selective reduction of cholesterol in HDL2 fraction by Probucol in familial hyt~x:holesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol 1988; 62: 66B-72B.
  • 10Sawayama Y, Shimizu C, Maeda N, et al. Effects of Probucol and pravastatin on common carotid atherosclerosis in patients with asyrr~tornalic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). JAm Coll Cardio12002; 39: 610-616.

共引文献6

同被引文献91

引证文献15

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部